Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 13, 2018

Primary Completion Date

January 13, 2021

Study Completion Date

January 13, 2021

Conditions
Phenylketonuria (PKU)
Interventions
DRUG

Pegvaliase

40-60mg/day

Trial Locations (17)

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

19134

St. Christopher's Hospital for Children, Philadelphia

32610

University of Florida, Gainesville

33606

University of South Florida, Tampa

37232

Vanderbilt University Medical Center, Nashville

40536

University of Kentucky Medical Center, Lexington

46202

Indiana CTSI Clinical Research Center, Indianapolis

48201

Wayne State University, Center for Molecular Medicine and Genetics, Pediatrics and Pathology, Detroit

53226

Medical College of Milwaukee, Milwaukee

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

65201

University of Missouri Health Care, Columbia

68198

University of Nebraska Medical Center, Omaha

73104

University of Oklahoma Health Science Center, Oklahoma City

77030

University of Texas Health Science Center at Houston, Houston

97239

Oregon Health and Science University, Portland

07960

Morristown Medical Center, Morristown

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY